Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU: A Multicenter, Randomized Controlled Trial
Primary result · Time to clinical improvementResult — go to the resultDifference −2.0 days 95% CI −3.0 to 0.0Authors' conclusion
We found that compared with the use of CMTs alone, mNGS combined with CMTs reduced the time to clinical improvement for patients with SCAP.
Study context
- Population
- Patients with severe community-acquired pneumonia (SCAP) in the ICUrandomized
- Participants
- 349 patients
- Comparison
- Metagenomic next-generation sequencing (mNGS) vs CMT
- mNGSn = 179
- CMTn = 170reference
- Primary endpoint
- Time to clinical improvement (time from randomization to improvement of two points on a six-category ordinal scale or ICU discharge, whichever first)
Methodological detailsmulticentre, open-label, 10 ICUs, Randomized between January 1, 2021, and November 18, 2022
- Multicentre
- Open-label
- 10 ICUs
- Randomized between January 1, 2021, and November 18, 2022
Primary result
Time to clinical improvement
Difference
−2.0 days
95% CI −3.0 to 0.0
By group
mNGS vs CMT
difference −2.0 days (95% CI −3.0 to 0.0)
As reported in the abstract
Secondary outcomes
Clinical improvement within 14 days
Clinical improvement within 14 days
- Significantly higher in the mNGS group
Other secondary outcomes
- No significant difference
Original publication
Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes of Patients With Severe Community-Acquired Pneumonia in the ICU: A Multicenter, Randomized Controlled Trial. Chest. Published 25 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →